药学学报, 2016, 51(6): 931-937
引用本文:
翁娅韵, 金李莎, 汪宇清, 宋飞凤, 李丽萍, 周慧, 曾苏, 蒋惠娣. 稳定表达人OCTN1/OCTN2的细胞模型构建及应用[J]. 药学学报, 2016, 51(6): 931-937.
WENG Ya-yun, JIN Li-sha, WANG Yu-qing, SONG Fei-feng, LI Li-ping, ZHOU Hui, ZENG Su, JIANG Hui-di. Establishment and application of cell models with stable expression of hOCTN1/2[J]. Acta Pharmaceutica Sinica, 2016, 51(6): 931-937.

稳定表达人OCTN1/OCTN2的细胞模型构建及应用
翁娅韵1,2, 金李莎1, 汪宇清1, 宋飞凤1, 李丽萍1, 周慧1, 曾苏1, 蒋惠娣1
1. 浙江大学药学院药物代谢与分析实验室, 浙江省抗肿瘤药物重点实验室, 浙江 杭州 310058;
2. 浙江工业大学长三角绿色制药协同创新中心, 浙江 杭州 310014
摘要:
人肉碱/有机阳离子转运体1和2(human carnitine/organic cation transporters, hOCTN1/hOCTN2)参与多种内、外源物质转运。本研究拟构建稳定表达hOCTN1/2的细胞模型,用于药物与转运体相互作用的研究。将重组质粒pcDNA3.1(+)-hOCTN1/2转染MDCK细胞,经G418抗性筛选挑取单克隆细胞株,以麦角硫因(OCTN1经典底物)或米屈肼(OCTN2经典底物)进行细胞积聚研究,挑选功能最优的MDCK-hOCTN1/2细胞株为模型细胞。进一步考察经典底物的积聚动力学,并探究内源物、生物碱、黄酮及普利类药物对hOCTN1/2的抑制作用。结果显示,麦角硫因在MDCK-hOCTN1细胞上的积聚量为mock细胞的122倍, KmVmax为8.19± 0.61 μmol·L-1和1427± 49 pmol·mg-1(protein)·min-1;米屈肼在MDCK-hOCTN2细胞上的积聚量为阴性对照(mock细胞)的108倍, KmVmax为52.3± 4.3 μmol·L-1和2454± 64 pmol·mg-1(protein)·min-1。多巴胺、谷氨酰胺、胡椒碱、黄连素、荷叶碱、赖诺普利和福辛普利对hOCTN1/2有显著的抑制作用。因此,本研究构建的MDCK-hOCTN1/2细胞模型可应用于药物与hOCTN1/hOCTN2相互作用研究。
关键词:    人肉碱/有机阳离子转运体1和2      麦角硫因      米屈肼      抑制作用      犬肾上皮细胞     
Establishment and application of cell models with stable expression of hOCTN1/2
WENG Ya-yun1,2, JIN Li-sha1, WANG Yu-qing1, SONG Fei-feng1, LI Li-ping1, ZHOU Hui1, ZENG Su1, JIANG Hui-di1
1. Laboratory of Pharmaceutical Analysis and Drug Metabolism, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China;
2. Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China
Abstract:
Human carnitine/organic cation transporter 1 and 2(hOCTN1 and hOCTN2) mediate transport of endogenous and exogenous compounds. The present study aimed to establish cell models with stable expression of hOCTN1 or hOCTN2 to study interactions with compounds and transporters. MDCK cells were transfected with pcDNA3.1(+) plasmid vector containing hOCTN1 or hOCTN2(pcDNA3.1(+)-hOCTN1/2), several stable transfected clones were obtained after G418 screening. hOCTN1 and hOCTN2 clones were screened with ergothioneine and mildronate respectively as substrates to identify the best candidates. We explored interactions of endogenous substances, alkaloids, flavonoids and ACEIs with hOCTN1/2. As a result, the cellular accumulation of ergothioneine in MDCK-hOCTN1 or mildronate in MDCK-hOCTN2 was 122 and 108 folds of the control cells, respectively. The kinetic parameters, Km and Vmax of ergothioneine, mediated by MDCK-hOCTN1, were 8.19±0.61 μmol·L-1 and 1427±49 pmol·mg-1(protein)·min-1; while Km and Vmax of mildronate by MDCKhOCTN2 were 52.3±4.3 μmol·L-1 and 2454±64 pmol·mg-1(protein)·min-1. Dopamine, glutamine, piperine, berberine, nuciferine, lisinopril and fosinopril could inhibit ergothioneine or mildronate uptake by MDCKhOCTN1/2. In conclusion, cell models with good stable hOCTN1 and hOCTN2 functions have been established successfully, which can be applied to the study of interactions between compounds and transporters of hOCTN1 and hOCTN2.
Key words:    human carnitine/organic cation transporter 1 and 2    ergothioneine    mildronate    inhibition    Madin-Darby canine kidney cell   
收稿日期: 2015-10-19
DOI: 10.16438/j.0513-4870.2015-0949
基金项目: 国家自然科学基金资助项目(81373474);浙江省科技厅资助项目(2015C33162).
通讯作者: 蒋惠娣,Tel/Fax:86-571-88208408,E-mail:hdjiang@zju.edu.cn
Email: hdjiang@zju.edu.cn
相关功能
PDF(1019KB) Free
打印本文
0
作者相关文章
翁娅韵  在本刊中的所有文章
金李莎  在本刊中的所有文章
汪宇清  在本刊中的所有文章
宋飞凤  在本刊中的所有文章
李丽萍  在本刊中的所有文章
周慧  在本刊中的所有文章
曾苏  在本刊中的所有文章
蒋惠娣  在本刊中的所有文章

参考文献:
[1] Tamai I, Yabuuchi H, Nezu J, et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1[J]. FEBS Lett, 1997, 419:107-111.
[2] Carsten E, Sabrina N, Mohammed A, et al. OCTN1-mediated ergothioneine uptake protects lung epithelial cells from tobacco smoke-induced damage[J]. FASEB J, 2015, 29:970-975.
[3] Nakamichi N, Shima H, Asano S, et al. Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin[J]. J Pharm Sci, 2013, 102:3407-3417.
[4] Urban T, Brown C, Castro R, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin[J]. Clin Pharmacol Ther, 2008, 83:416-421.
[5] Jong N, Nakanishi T, Liu J, et al. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons[J]. J Pharmacol Exp Ther, 2011, 338:537-547.
[6] Tamai I, Ohashi R, Nezu J, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2[J]. J Biol Chem, 1998, 273:20378-20382.
[7] Yasuro F, Tomoko S, Yukio K, et al. Muscle contraction increases carnitine uptake via translocation of OCTN2[J]. Biochem Biophys Res Commun, 2012, 418:774-779.
[8] Garrett Q, Xu S, Simmons P, et al. Expression and localization of carnitine/organic cation transporter OCTN1 and OCTN2 in ocular epithelium[J]. Invest Ophthalmol Vis Sci, 2008, 49:4844-4849.
[9] Tu MJ, Li LP, Lei HM, et al. Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity[J].Toxicology, 2014, 322:34-42.
[10] Toshimichi N, Kenji Y, Hikaru Y, et al. Functional characterization of ergothioneine transport by rat organic cation/carnitine transporter Octn1(slc22a4)[J]. Biol Pharm Bull, 2008, 31:1580-1584.
[11] Wang K, Sun SY, Li LP, et al. Involvement of organic cation transporter 2 inhibition in potential mechanism of antidepressant action[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2014, 53:90-97.
[12] Lei HM, Sun SY, Li LP, et al. Establishment of MDCK cell models expressing human MATE1 or co-expressing with human OCT1 or OCT2[J]. Acta Pharm Sin (药学学报), 2015, 50:842-847.
[13] Ikumi T. Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs:SLC22A4, SLC22A5 and Slc22a21)[J]. Biopharm Drug Dispos, 2013, 34:29-44.
[14] Silke G, Christian F, Markus B, et al. The carnitine transporter slc22a5 is not a general drug transporter, but it efficiently translocates mildronate[J]. Drug Metab Dispos, 2009, 37:330-337.
[15] Hikaru Y, Ikumi T, Jun N, et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and PH-dependent transport of organic cations[J]. J Pharmacol Exp Ther, 1998, 289:768-773.
[16] Toshimichi N, Shigeki S, Daisuke K, et al. Decreased proliferation and erythroid differentiation of K562 cells by siRNA induced depression of OCTN1(SLC22A4) transporter gene[J]. Pharm Res, 2007, 24:1628-1635.
[17] Dirk G, Stephanie H, Stefan G, et al. Discovery of the ergothioneine transporter[J]. Proc Natl Acad Sci USA, 2005, 102:5256-5261.